Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT6L509)

• DTT Name: Coagulation factor IIa (F2) DTT Info
• Gene Name: F2

Molecule-Related Drug & Molecule List

11 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anisindione	DM2C48U	Coagulation defect	3B10.0	Approved	[1]
Argatroban	DMFI46A	Thrombosis	DB61-GB90	Approved	[2]
ATryn antithrombin	DM79Y2T	Multiple sclerosis	8A40	Approved	[3]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[4]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[5]
Desirudin Recombinant	DM2BTFN	Coagulation defect	3B10.0	Approved	[6]
Human prothrombin complex concentrate	DMPHVQ1	Bleeding disorder	GA20-GA21	Approved	[7]
Lepirudin	DM1I3D5	Thrombocytopenia	3B64	Approved	[8]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[9]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[10]
Hirudin	DMYOC29	N. A.	N. A.	Phase 4	[11]

16 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MELAGATRAN	DM4W8RE	N. A.	N. A.	Phase 3	[12]
SR-123781A	DM5WQ2U	Venous thrombosis	BA43	Phase 2/3	[13]
EFEGATRAN SULFATE HYDRATE	DMX4RSD	Myocardial infarction	BA41-BA43	Phase 2	[14]
EP-217609	DMPC4EK	Thrombosis	DB61-GB90	Phase 2	[15]
LB-30870	DM0OHX3	Myocardial infarction	BA41-BA43	Phase 2	[14]
NU-172	DMORNVB	Thrombosis	DB61-GB90	Phase 2	[16]
Odiparcil	DMWCBY7	Cardiovascular disease	BA00-BE2Z	Phase 2	[17]
Pegmusirudin	DMPD3X6	Angina pectoris	BA40	Phase 2	[7]
Recombinant RGD-hirudin	DMV0A28	Thrombosis	DB61-GB90	Phase 2	[18]
TF0023	DMF61ML	Heart attack	BA41	Phase 2	[19]
AZD-8165	DM8DMI0	Thrombosis	DB61-GB90	Phase 1	[7]
DP-4088	DMXZ6A0	Coagulation defect	3B10.0	Phase 1	[7]
EP-42675	DMKR3GD	Thrombosis	DB61-GB90	Phase 1	[20]
RWJ-671818	DMJVCS1	Thrombosis	DB61-GB90	Phase 1	[21]
Solulin	DMB3WJF	Thrombosis	DB61-GB90	Phase 1	[22]
SSR-128428	DMOJA7N	Thrombosis	DB61-GB90	Phase 1	[23]

29 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ximelagatran	DMABRJL	Coagulation defect	3B10.0	Withdrawn from market	[24]
AZD0837	DMA9Q2V	Nonvalvular atrial fibrillation	BC81.3Y	Discontinued in Phase 2	[25]
Dermolastin	DM6WSU2	Atopic dermatitis	EA80	Discontinued in Phase 2	[26]
INOGATRAN	DM6HDO3	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[27]
Napsagatran	DM8L4Z0	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[28]
SSR-182289	DMN7BM3	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[14]
Vasoflux	DMHCOFM	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[29]
ARC-183	DMKLCRI	Blood forming organ disorder	JB64.1	Discontinued in Phase 1	[30]
BCX-1470	DMN2XR7	Bleeding disorder	GA20-GA21	Discontinued in Phase 1	[31]
CJC-1004	DM3Q8UW	Thrombosis	DB61-GB90	Discontinued in Phase 1	[32]
CVS-1123	DMDRFZV	Myocardial infarction	BA41-BA43	Discontinued in Phase 1	[33]
GW-473178	DMRQVI9	Heart arrhythmia	BC65	Discontinued in Phase 1	[34]
Licostinel	DMMWCU3	Neurological disorder	6B60	Discontinued in Phase 1	[35]
MPC-0920	DMMVG34	Thrombosis	DB61-GB90	Discontinued in Phase 1	[36]
S-18326	DMX59E8	Myocardial infarction	BA41-BA43	Discontinued in Phase 1	[14]
UK-156406	DMGFPIY	Myocardial infarction	BA41-BA43	Discontinued in Phase 1	[14]
BCH-2763	DM3TP8X	Thrombosis	DB61-GB90	Terminated	[37]
BMS-189664	DMV3B5Y	Myocardial infarction	BA41-BA43	Terminated	[14]
CVS-995	DMMDO3X	Myocardial infarction	BA41-BA43	Terminated	[38]
DuP 714	DMZOCHT	Thrombosis	DB61-GB90	Terminated	[39]
Efegatran	DM7ROS1	N. A.	N. A.	Terminated	[39]
GS-522	DMT6S9B	Thrombosis	DB61-GB90	Terminated	[40]
Hementin	DM5HMZW	Thrombosis	DB61-GB90	Terminated	[41]
L-373890	DMOKZ2V	Thrombosis	DB61-GB90	Terminated	[42]
L-374,087	DMK2QW0	Thrombosis	DB61-GB90	Terminated	[43]
LB30057	DMYGJCL	N. A.	N. A.	Terminated	[44]
Org-34092	DM3VWZF	Thrombosis	DB61-GB90	Terminated	[7]
PPACK	DMLY2TN	N. A.	N. A.	Terminated	[39]
SR-80027A	DM6ASLF	Thrombosis	DB61-GB90	Terminated	[45]

86 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	DMNVDLI	Discovery agent	N.A.	Investigative	[46]
(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	DMT9FZD	Discovery agent	N.A.	Investigative	[46]
(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone	DMD4Z6H	Discovery agent	N.A.	Investigative	[46]
(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	DM31OSD	Discovery agent	N.A.	Investigative	[46]
(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone	DMBPL3J	Discovery agent	N.A.	Investigative	[46]
(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone	DMIDUO9	Discovery agent	N.A.	Investigative	[46]
1,2,3,4,6-penta-O-galloyl-beta-D-glucose	DMTK650	Discovery agent	N.A.	Investigative	[47]
1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE	DMBTLIJ	Discovery agent	N.A.	Investigative	[48]
1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	DMG5MNZ	Discovery agent	N.A.	Investigative	[46]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine	DM3UMYD	Discovery agent	N.A.	Investigative	[49]
2-NAPHTHALENESULFONIC ACID	DMZ4LJ7	Discovery agent	N.A.	Investigative	[48]
2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine	DMFXKN1	Discovery agent	N.A.	Investigative	[50]
3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate	DMZ0F7E	Discovery agent	N.A.	Investigative	[51]
4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL	DM3D8OK	Discovery agent	N.A.	Investigative	[48]
4-(3,4-Diethoxy-benzylamino)-benzamidine	DMIZXYM	Discovery agent	N.A.	Investigative	[52]
4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine	DME3PUT	Discovery agent	N.A.	Investigative	[52]
4-hydroxyphenylpyruvic acid	DM0564K	Discovery agent	N.A.	Investigative	[48]
4-iodobenzo[b]thiophene 2-carboxamidine	DMXAEGF	N. A.	N. A.	Investigative	[48]
4-TERT-BUTYLBENZENESULFONIC ACID	DMGCYS1	Discovery agent	N.A.	Investigative	[48]
4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE	DMJI6AM	Discovery agent	N.A.	Investigative	[48]
5-desgalloylstachyurin	DM6TM1L	Discovery agent	N.A.	Investigative	[47]
6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE	DMA2CPG	Discovery agent	N.A.	Investigative	[48]
AC-(D)PHE-PRO-BOROHOMOLYS-OH	DMZ0RP5	Discovery agent	N.A.	Investigative	[48]
AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH	DMPHV7K	Discovery agent	N.A.	Investigative	[48]
AC-(D)PHE-PRO-BOROLYS-OH	DM2YWRL	Discovery agent	N.A.	Investigative	[48]
Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir	DMMJ4I5	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir	DM8TH4B	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir	DMQVRHG	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir	DMTU0HR	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir	DMXECFJ	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir	DM5N6YE	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir	DMEL2GK	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir	DMCN48J	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir	DMLK5I0	Discovery agent	N.A.	Investigative	[53]
Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir	DMLZ5R6	Discovery agent	N.A.	Investigative	[53]
BENZOTHIAZOLE	DMV7MPL	Discovery agent	N.A.	Investigative	[48]
Beta-(2-Naphthyl)-Alanine	DMP21ZO	Discovery agent	N.A.	Investigative	[48]
Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide	DMQXMKB	Discovery agent	N.A.	Investigative	[48]
BMS-344577	DM9WRUG	Discovery agent	N.A.	Investigative	[54]
BMS-740808	DMQ24TI	Discovery agent	N.A.	Investigative	[55]
bufrudin	DMWQ3RH	Discovery agent	N.A.	Investigative	[56]
CASUARIIN	DM5E21C	Discovery agent	N.A.	Investigative	[47]
CHLORODYSINOSIN A	DMGS3FI	Discovery agent	N.A.	Investigative	[57]
COCHINCHINENENE B	DMCSAIJ	Discovery agent	N.A.	Investigative	[58]
COCHINCHINENIN B	DMIGB7N	Discovery agent	N.A.	Investigative	[58]
CRA_8696	DM3IZOP	Discovery agent	N.A.	Investigative	[48]
CVS-1578	DMO9UMK	Discovery agent	N.A.	Investigative	[59]
Cyclotheonamide E	DM8HG0K	Discovery agent	N.A.	Investigative	[60]
Cyclotheonamide E4	DM2E5VZ	Discovery agent	N.A.	Investigative	[60]
Cyclotheonamide E5	DMCA76M	Discovery agent	N.A.	Investigative	[60]
D-leucyl-N-(3-chlorobenzyl)-L-prolinamide	DMVN93B	Discovery agent	N.A.	Investigative	[48]
D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide	DMIFCHL	Discovery agent	N.A.	Investigative	[48]
D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide	DMGD7JM	Discovery agent	N.A.	Investigative	[48]
D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide	DM5XHA6	Discovery agent	N.A.	Investigative	[48]
D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide	DMV9RAN	Discovery agent	N.A.	Investigative	[48]
D-phenylalanyl-N-benzyl-L-prolinamide	DMHNR63	Discovery agent	N.A.	Investigative	[48]
D-Pro-Phe-Arg chloromethyl ketone	DMRJQ8X	Discovery agent	N.A.	Investigative	[61]
Desirudine	DMB07WE	Discovery agent	N.A.	Investigative	[9]
DYSINOSIN A	DMU42C1	Discovery agent	N.A.	Investigative	[57]
Enoxaprin	DMYJ8ZB	Discovery agent	N.A.	Investigative	[62]
Gamma-Carboxy-Glutamic Acid	DMZMCT0	Discovery agent	N.A.	Investigative	[63]
GR-133686	DMQH8PK	Discovery agent	N.A.	Investigative	[64]
Haempatch	DMO6MGJ	Bleeding disorder	GA20-GA21	Investigative	[7]
Hemi-Babim	DMXP276	Discovery agent	N.A.	Investigative	[48]
Heparin-Cantithrombin III	DM7U491	Discovery agent	N.A.	Investigative	[65]
L-370,518	DMC1Z0L	Discovery agent	N.A.	Investigative	[66]
L-375378	DMQWKPM	Discovery agent	N.A.	Investigative	[67]
LB30812	DM3H9ZY	Discovery agent	N.A.	Investigative	[68]
Lysophosphotidylserine	DMIG3FX	Discovery agent	N.A.	Investigative	[63]
Macrocyclic tripeptide motif	DMFULZO	Discovery agent	N.A.	Investigative	[69]
Melogatran	DME54M7	Discovery agent	N.A.	Investigative	[65]
Methyl L-phenylalaninate	DMBHUKV	Discovery agent	N.A.	Investigative	[48]
METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE	DMR7HV3	Discovery agent	N.A.	Investigative	[48]
N4-(N,N-diphenylcarbamoyl)-aminoguanidine	DMYPZMO	Discovery agent	N.A.	Investigative	[48]
OSCILLARIN	DMK6X5P	Discovery agent	N.A.	Investigative	[57]
Pedunculagin	DMKLRCX	Discovery agent	N.A.	Investigative	[47]
RAZAXABAN	DMPML15	Discovery agent	N.A.	Investigative	[70]
RWJ-50353	DMRPYGX	Discovery agent	N.A.	Investigative	[71]
S-2238	DM3GS2X	Discovery agent	N.A.	Investigative	[72]
SC-79407	DMD71VB	Discovery agent	N.A.	Investigative	[43]
TB-101	DMCZIFS	Bleeding disorder	GA20-GA21	Investigative	[7]
TB-102	DMUN8CG	Bleeding disorder	GA20-GA21	Investigative	[7]
Tellimagrandin II	DM60HU5	Discovery agent	N.A.	Investigative	[47]
Tumor vascular thrombogen	DMIRQ65	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
VE-04051645	DM3GADP	Solid tumour/cancer	2A00-2F9Z	Investigative	[7]
Vitamin K	DMN6EZY	Discovery agent	N.A.	Investigative	[73]

References

• [1] Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
• [2] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
• [3] Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
• [4] New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
• [5] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [8] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
• [9] New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
• [10] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [11] Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69.
• [12] Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53.
• [13] SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95.
• [16] Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011; 18(27): 4206-4214.
• [17] A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96.
• [18] The NMR solution structure of recombinant RGD-hirudin. Biochem Biophys Res Commun. 2007 Aug 17;360(1):103-8.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33.
• [21] Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RW... J Med Chem. 2010 Feb 25;53(4):1843-56.
• [22] The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 2011 Jun;9(6):1174-82.
• [23] Company report (Sanofi) (drug: FY2008)
• [24] Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol In Vitro. 2009 Oct;23(7):1305-10.
• [25] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [26] Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
• [27] Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J Pharmacol Exp Ther. 1996 Jun;277(3):1276-83.
• [28] Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther. 1996 Apr;277(1):71-8.
• [29] Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation. 1999 Feb 9;99(5):682-9.
• [30] A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost. 2012 May;10(5):870-80.
• [31] Recent Developments in Low Molecular Weight Complement Inhibitors. Mol Immunol. 2009 December; 47(2-3): 185-195.
• [32] Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408.
• [33] CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol. 1997 Feb;29(2):240-9.
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015039)
• [35] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
• [36] Clinical pipeline report, company report or official report of MYRIAD GENETICS, INC.
• [37] BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost. 1998 Feb;79(2):431-8.
• [38] Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic. Protein Sci. 1996 Mar;5(3):422-33.
• [39] Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204.
• [40] A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum. Pharm Res. 1995 Dec;12(12):1937-42.
• [41] Hementin: anticoagulant protease from the salivary gland of the leech Haementeria ghilianii. J Lab Clin Med. 1984 Jan;103(1):44-58.
• [42] L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Lett. 1998 Apr 7;8(7):817-22.
• [43] Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
• [44] Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor. Thromb Haemost. 2003 Jan;89(1):104-11.
• [45] Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood. 1994 Oct 15;84(8):2571-7.
• [46] N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
• [47] Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
• [48] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [49] Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71.
• [50] Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26.
• [51] 3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J Med Chem. 2005 Dec 1;48(24):7592-603.
• [52] Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.
• [53] Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3.
• [54] Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9.
• [55] Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett. 2008 Jan 15;18(2):749-54.
• [56] Leech therapeutic applications.Indian J Pharm Sci.2013 Mar;75(2):127-37.
• [57] From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32.
• [58] Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis. J Nat Prod. 2007 Oct;70(10):1570-7.
• [59] Design and construction of novel thrombin inhibitors featuring P3-P4 quaternary lactam dipeptide surrogates. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2501-6.
• [60] Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod. 2002 Mar;65(3):259-61.
• [61] Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.
• [62] Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv. 1994 Jun;49(6):424-31.
• [63] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [64] 5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor. Bioorg Med Chem Lett. 1998 Nov 3;8(21):2955-60.
• [65] Thrombin inhibitors in acute coronary artery disease. Eur Heart J. 2002 Aug;23(15):1142-4.
• [66] Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost. 1998 Mar;79(3):656-62.
• [67] Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. Bioorg Med Chem Lett. 2003 Jan 20;13(2):161-4.
• [68] Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. J Med Chem. 2003 Aug 14;46(17):3612-22.
• [69] Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif, Bioorg. Med. Chem. Lett. 6(24):2947-2952 (1996).
• [70] Phenyltriazolinones as potent factor Xa inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1373-7.
• [71] Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95.
• [72] Screening for selective thrombin inhibitors in mushrooms. Blood Coagul Fibrinolysis. 2001 Mar;12(2):123-8.
• [73] Plasma levels of protein C and vitamin K-dependent coagulation factors in patients on long-term oral anticoagulant therapy. Tohoku J Exp Med. 1986 Aug;149(4):351-7.